サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791470

抗体薬物複合体受託製造の世界市場

Antibody Drug Conjugates Contract Manufacturing

出版日
ページ情報
英文 168 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
抗体薬物複合体受託製造の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 168 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗体薬物複合体受託製造の世界市場は2030年までに291億米ドルに達する見込み

2024年に134億米ドルと推定された抗体薬物複合体受託製造の世界市場は、2024～2030年の分析期間においてCAGR 13.8%で成長し、2030年には291億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである骨髄腫の状態は、CAGR 15.5%を記録し、分析期間終了時には160億米ドルに達すると予測されます。Lymphome Conditionセグメントの成長率は、分析期間中CAGR 12.8%と推定されます。

米国市場は35億米ドルと推定、中国はCAGR 12.9％で成長予測

米国の抗体薬物複合体受託製造市場は、2024年に35億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに45億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.9%と11.7%と予測されています。欧州では、ドイツがCAGR 9.9%で成長すると予測されています。

世界の抗体薬物複合体（ADC）受託製造市場- 主要動向と促進要因のまとめ

抗体薬物複合体はなぜ製薬業界で注目を集めているのか？

抗体薬物複合体（ADC）は、モノクローナル抗体の特異性と細胞毒性薬剤の効能を併せ持つ画期的な標的治療薬として登場しました。これらの革新的なバイオ医薬品は、全身毒性を抑えながら腫瘍を正確に標的化する能力を提供し、がん治療のパラダイムを変革しています。個別化医療の台頭とがん生物学への理解の深まりがADCの開発に拍車をかけ、生物製剤市場で最も急成長している分野のひとつとなっています。従来の化学療法とは異なり、ADCは健康な組織を温存しながらがん細胞に選択的に細胞毒性ペイロードを送達するため、治療成績が大幅に改善します。製薬会社がADCベースの治療に力を入れるにつれ、生物製剤、コンジュゲーション化学、高力価薬剤の取り扱いに精通した専門製造受託機関（CMO）の需要が急増しています。

ADCの開発を促進する技術的進歩とは？

抗体薬物複合体技術の急速な進化は、リンカー化学、ペイロードの最適化、部位特異的コンジュゲーション技術の進歩によってもたらされています。最新のADCは、リンカーの安定性が向上し、標的細胞に到達したときにのみ細胞毒性を持つペイロードが放出されるようになっています。さらに、ピロロベンゾジアゼピン（PBD）二量体やチューブリン阻害剤など、より高い効力と選択性を持つ革新的なペイロードが、ADCの治療用途を拡大しつつあります。THIOMABや糖鎖工学的アプローチを含む部位特異的コンジュゲーション技術は、薬物対抗体比（DAR）の制御を強化し、より均質で効果的なADC製剤につながっています。AIを活用した創薬とバイオプロセスの最適化は、ADC開発をさらに合理化し、より迅速でコスト効率の高い生産を可能にしています。

ADC受託製造市場を主導する企業と地域は？

世界のADC受託製造市場は投資の急増を目の当たりにしており、大手CMOやバイオテクノロジー企業は業界の需要に応えるために能力を拡大しています。米国は依然としてADC製造における支配的なプレーヤーであり、Lonza、Catalent、WuXi Biologicsなどの開発・製造受託機関（CDMO）がADC製造用の高濃度設備に投資しています。スイス、ドイツ、中国、韓国のような国々がADC受託製造の主要拠点として台頭しており、欧州とアジア太平洋も急速な拡大を目の当たりにしています。ADC開発に注力するバイオベンチャー企業の増加により、信頼できるアウトソーシング・パートナーの必要性がさらに高まり、製薬大手と専門CMOの協力関係が促進されています。

ADC受託製造の成長を促進する市場要因とは？

ADC受託製造市場の成長は、標的がん治療の採用の増加、バイオコンジュゲーション技術の進歩、ADC製造プロセスの複雑化など、いくつかの要因によってもたらされます。高いインフラコストと厳しい規制要件により、製造のアウトソーシングへのシフトが専門CDMOの需要を促進しています。さらに、ADCベースの治療薬、特にがんや自己免疫疾患の臨床パイプラインの拡大が、市場の成長を後押ししています。適正製造基準（GMP）に準拠した製造が重視されるようになり、FDAやEMAなどの機関による厳しい規制監督も加わって、経験豊富な受託製造業者への依存度がさらに高まっています。さらに、二重薬物複合体や免疫調節ADCを含む次世代ADCの研究が進んでおり、受託製造の分野で新たな機会が生まれると期待されています。ADCが標的治療に革命を起こし続ける中、受託製造業者はバイオ医薬品イノベーションの未来を形作る上で極めて重要な役割を果たす態勢を整えています。

セグメント

病態タイプ（骨髄腫病態、リンパ腫病態、その他の病態）;リンカー（開裂性リンカー、非開裂性リンカー）

調査対象企業の例

  • AbbVie Contract Manufacturing
  • Abzena
  • AGC Biologics
  • Axplora Group GmbH
  • ChemExpress
  • EirGenix, Inc.
  • MilliporeSigma
  • Piramal Pharma Solutions
  • Single Use Support GmbH
  • Sterling Pharma Solutions Limited
  • Veranova
  • WuXi Biologics

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29179

Global Antibody Drug Conjugates Contract Manufacturing Market to Reach US$29.1 Billion by 2030

The global market for Antibody Drug Conjugates Contract Manufacturing estimated at US$13.4 Billion in the year 2024, is expected to reach US$29.1 Billion by 2030, growing at a CAGR of 13.8% over the analysis period 2024-2030. Myeloma Condition, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$16.0 Billion by the end of the analysis period. Growth in the Lymphome Condition segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 12.9% CAGR

The Antibody Drug Conjugates Contract Manufacturing market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 11.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Are Antibody Drug Conjugates Gaining Traction in the Pharmaceutical Industry?

Antibody-drug conjugates (ADCs) have emerged as a revolutionary class of targeted therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. These innovative biopharmaceuticals are transforming oncology treatment paradigms, offering precise tumor-targeting capabilities with reduced systemic toxicity. The rise of personalized medicine and the growing understanding of cancer biology have fueled the development of ADCs, making them one of the fastest-growing segments in the biologics market. Unlike conventional chemotherapy, ADCs selectively deliver cytotoxic payloads to cancer cells while sparing healthy tissues, significantly improving treatment outcomes. As pharmaceutical companies intensify their focus on ADC-based therapies, the demand for specialized contract manufacturing organizations (CMOs) with expertise in biologics, conjugation chemistry, and high-potency drug handling is surging.

What Technological Advances Are Enhancing the Development of ADCs?

The rapid evolution of antibody-drug conjugate technology is driven by advancements in linker chemistry, payload optimization, and site-specific conjugation techniques. Modern ADCs are benefiting from improved linker stability, ensuring that the cytotoxic payload is released only upon reaching the target cells. Additionally, innovative payloads with higher potency and selectivity, such as pyrrolobenzodiazepine (PBD) dimers and tubulin inhibitors, are expanding the therapeutic applications of ADCs. Site-specific conjugation technologies, including THIOMAB and glycoengineering approaches, are enhancing drug-to-antibody ratio (DAR) control, leading to more homogenous and effective ADC formulations. AI-driven drug discovery and bioprocess optimization are further streamlining ADC development, allowing for faster and more cost-effective production.

Which Companies and Regions Are Leading the ADC Contract Manufacturing Market?

The global ADC contract manufacturing market is witnessing a surge in investments, with leading CMOs and biotechnology firms scaling up their capabilities to meet industry demand. The United States remains a dominant player in ADC manufacturing, with contract development and manufacturing organizations (CDMOs) such as Lonza, Catalent, and WuXi Biologics investing in high-containment facilities for ADC production. Europe and Asia-Pacific are also witnessing rapid expansion, with countries like Switzerland, Germany, China, and South Korea emerging as key hubs for ADC contract manufacturing. The rising number of biotech startups focused on ADC development has further intensified the need for reliable outsourcing partners, fostering collaborations between pharmaceutical giants and specialized CMOs.

What Are the Market Forces Driving the Growth of ADC Contract Manufacturing?

The growth in the ADC contract manufacturing market is driven by several factors, including the rising adoption of targeted cancer therapies, advancements in bioconjugation technology, and the increasing complexity of ADC production processes. The shift towards outsourcing manufacturing due to high infrastructure costs and stringent regulatory requirements has propelled demand for specialized CDMOs. Additionally, the expansion of clinical pipelines for ADC-based therapies, particularly in oncology and autoimmune diseases, is fueling market growth. The growing emphasis on Good Manufacturing Practice (GMP)-compliant production, along with stringent regulatory oversight from agencies like the FDA and EMA, has further increased the reliance on experienced contract manufacturers. Moreover, the ongoing research into next-generation ADCs, including dual-drug conjugates and immune-modulating ADCs, is expected to create new opportunities in the contract manufacturing space. As ADCs continue to revolutionize targeted therapy, contract manufacturers are poised to play a pivotal role in shaping the future of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Antibody Drug Conjugates Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Condition Type (Myeloma Condition, Lymphome Condition, Other Conditions); Linker (Cleavable Linker, Non-Cleavable Linker)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AbbVie Contract Manufacturing
  • Abzena
  • AGC Biologics
  • Axplora Group GmbH
  • ChemExpress
  • EirGenix, Inc.
  • MilliporeSigma
  • Piramal Pharma Solutions
  • Single Use Support GmbH
  • Sterling Pharma Solutions Limited
  • Veranova
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Antibody Drug Conjugates Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Targeted Cancer Therapies Driving ADC Market Expansion
    • Expansion of Biopharma Outsourcing for ADC Development and Manufacturing
    • Rising Investments in Novel ADC Linker Technologies for Enhanced Drug Efficacy
    • Surge in Demand for High-Potency Active Pharmaceutical Ingredients (HPAPIs) in ADCs
    • Advancements in Site-Specific Conjugation Technologies for Improved Stability
    • Increasing Adoption of AI and Big Data Analytics in ADC Development
    • Expansion of Bioconjugation and Next-Generation Payload Technologies
    • Growing Strategic Collaborations Between Pharma Companies and ADC Manufacturers
    • Increasing Focus on Scalable and Cost-Effective ADC Manufacturing Solutions
    • Rising Demand for Fully Integrated ADC Manufacturing Services
    • Advancements in ADC Formulation Technologies for Enhanced Drug Delivery
    • Surge in Investments for Expanding ADC Manufacturing Capacity Worldwide
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Drug Conjugates Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Myeloma Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Myeloma Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Myeloma Condition by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lymphome Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Lymphome Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Lymphome Condition by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cleavable Linker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Non-Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Non-Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Non-Cleavable Linker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • CHINA
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of World 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030

IV. COMPETITION